GTG Launches GeneType, A Novel Comprehensive Risk Assessment Test That Covers 100% Of Women At Risk Of Developing Breast And Ovarian Cancer

Benzinga · May 29 20:03

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease,

is pleased to announce the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30, assesses a woman's risk of cancer due to hereditary, including those with common gene mutations, and sporadic disease.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

GTG Launches GeneType, A Novel Comprehensive Risk Assessment Test That Covers 100% Of Women At Risk Of Developing Breast And Ovarian Cancer

Risk Disclaimer